StreetInsider.com News Articles

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

Mon, 11 May 2026 08:41:00 -0400

BofA Securities 2026 Health Care Conference in Las Vegas, NV on Tuesday, May 12, 2026. Ian Somaiya, Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Matthew Philippe,

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Thu, 07 May 2026 07:00:00 -0400

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Thu, 07 May 2026 07:00:00 -0400

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Thu, 07 May 2026 07:00:00 -0400

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Thu, 07 May 2026 07:00:00 -0400

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Thu, 07 May 2026 07:00:00 -0400

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Thu, 07 May 2026 07:00:00 -0400

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK –

– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –

– Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 –

– Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American College of Cardiology Annual Scientific Session (ACC)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:57:00 -0400

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:57:00 -0400

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:57:00 -0400

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:57:00 -0400

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:57:00 -0400

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 01 May 2026 16:57:00 -0400

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

Wed, 08 Apr 2026 08:00:00 -0400

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:45 a.m. ET.

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

Wed, 08 Apr 2026 08:00:00 -0400

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:45 a.m. ET.

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

Wed, 08 Apr 2026 08:00:00 -0400

NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:45 a.m. ET.